GSK Territory Royalties Sample Clauses

GSK Territory Royalties. Subject to Section 16.7 (Certain Additional Remedies of GSK in Lieu of Termination) and the remainder of this Section 11.7 (Royalties), if Mersana exercises its Profit Share Election pursuant to Section 9.1.1 (Exercise of Profit Share Election), then, in partial consideration for the rights and licenses granted to GSK hereunder following the License Effective Date, including pursuant to Section 4.1 (License Grant to GSK), GSK shall pay to Mersana Royalties on aggregate annual Net Sales of all Licensed Products in the GSK Territory during a given Calendar Year at the royalty rates set forth in Table 11.7.2 below (the “GSK Territory Royalties”). GSK Territory Royalties with respect to a given Licensed Product in a given country shall only be paid during the Royalty Term for such Licensed Product in such country. -105- Table 11.7.2 – GSK Territory Royalties (Profit Share Election) Calendar Year Net Sales Royalty Rate For that portion of aggregate Net Sales in a Calendar Year of all Licensed Products in the GSK Territory up to and including $[**] [**]% For that portion of aggregate Net Sales in a Calendar Year of all Licensed Products in the GSK Territory greater than $[**] up to and including $[**] [**]% For that portion of aggregate Net Sales in a Calendar Year of all Licensed Products in the GSK Territory greater than $[**] up to and including $[**] [**]% For that portion of aggregate Net Sales in a Calendar Year of all Licensed Products in the GSK Territory greater than $[**] up to and including $[**] [**]% For that portion of aggregate Net Sales in a Calendar Year of all Licensed Products in the GSK Territory greater than $[**] [**]%
AutoNDA by SimpleDocs

Related to GSK Territory Royalties

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Net Sales The term “

  • Third Party Royalties Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

  • Royalties 8.1 In consideration of the license herein granted, LICENSEE shall pay royalties to LICENSOR as follows:

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

Time is Money Join Law Insider Premium to draft better contracts faster.